SUBSCRIBE
SUBSCRIBE
Tyler Patchen

Tyler Patchen

Freelance Writer

Tyler is a journalist with over six years of experience in the world of business journalism. He started his career with the Birmingham Business Journal in Birmingham, Alabama writing about health care, technology, sports business and education. He previously worked as a reporter for Endpoints News and for BioSpace, covering biopharma business and manufacturing. Tyler currently lives in Birmingham, Alabama and holds interests in reading, golf and is also a passionate sports fan. You can reach him at tpatchen94@gmail.com.

Pictured: Alzheimer's disease illustration/iStock,
Drug Development
Vivoryon’s Stock Craters After Alzheimer’s Candidate Fails Mid-Stage Trial
Varoglutamstat, a drug developed by German biotech Vivoryon Therapeutcs, did not hit its primary and secondary endpoints in a Phase IIb study in Alzheimer’s disease.
March 5, 2024
 · 
2 min read
 · 
Tyler Patchen
A view of a Bayer facility in Leverkusen, Germany/
Drug Development
Bayer Pays $310M to BridgeBio for ATTR-CM Treatment in Europe
As BridgeBio’s acoramidis inches closer to an FDA approval decision, Bayer on Monday inked a European licensing agreement for the transthyretin amyloid cardiomyopathy treatment.
March 4, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Cancer cell surrounded by cytokines/iSto
Drug Development
FogPharma Raises $145M in Series E Financing, Targets Solid Tumors
FogPharma’s latest financing round will help fund the ongoing clinical development of the company’s potential first-in-class intracellular TCF-blocking β-catenin inhibitor being evaluated in a Phase I/II study.
March 1, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: A dry eye/Kryuchka Yaroslav_Adobe Stock
Drug Development
Palatin’s Dry Eye Drug Candidate Flops in Phase III Trial
Palatin Technologies’ melanocortin agonist PL9643 came up short in a late-stage study evaluating its safety and efficacy.
March 1, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: 3D illustration of stem cells used for cell therapy
Business
Kenai Emerges from Stealth With $82M Series A, Targets Parkinson’s
Formerly known as Ryne Bio, Kenai Therapeutics emerged on Thursday with backing from several groups and has a cell therapy candidate going after Parkinson’s disease.
March 1, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Illustration showing a downward graph tr
Drug Development
Ironwood Nabs Phase III Win, Still Sees Stock Nosedive
Despite Ironwood Pharmaceuticals’ apraglutide getting positive late-stage study results in treating short bowel syndrome with intestinal failure, the stock plummeted nearly 40% on Thursday.
March 1, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: 3D rendering of antibody-drug conjugate/
Business
ADC Market Will Remain Hot in Oncology, Reaching $30B by 2028: Report
Antibody-drug conjugates are a breakthrough in targeted cancer therapy and will continue to attract big pharma investment over the next few years, finds a new report from market intelligence firm Evaluate.
March 1, 2024
 · 
3 min read
 · 
Tyler Patchen
Pictured: Wall sign of the Novo Nordisk Foundation and Novo Holdings in Denmark
Business
Novo Holdings, Forbion Lead Financing for Orbis Medicine’s $28M Seed Round
Denmark-based startup Orbis Medicines has launched with €26 million in seed funding in its drive to search for macrocycle drugs, with a focus on high-value oral alternatives to blockbuster biologics.
February 29, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Two business professionals in suits shaking hands
Business
Viatris, Idorsia Ink $350M R&D Pact for Two Phase III Assets
Under the research and development agreement announced Wednesday, Viatris is securing global rights to Idorsia’s late-stage heart and lupus candidates.
February 28, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: FDA sign at Washington D.C. headquarters
Drug Development
Minerva’s Schizophrenia Candidate Rejected by FDA in Complete Response Letter
The FDA has rejected Minerva Neurosciences’ treatment for negative symptoms in schizophrenia, noting a lack of data and other factors that led to the Complete Response Letter.
February 27, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Bullish money collage/ Nicole Bean for B
Biotech Beach
Janux’s Stock Skyrockets 172% on Positive Results for Two Candidates in Phase I Trials
Janux Therapeutics on Monday announced positive updated clinical data for both of its clinical programs in prostate cancer advanced or metastatic solid tumors.
February 27, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: GSK's headquarters in London
Drug Development
GSK Posts Positive Phase III Gonorrhea Results for Antibiotic Gepotidacin
The oral antibiotic, which is also in development for uncomplicated urinary tract infections, demonstrated non-inferiority to the most common treatment for gonorrhea.
February 26, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: GSK laboratories in Dresden, Germany
Drug Development
GSK Axes Collaboration with Vir Biotechnology on Anti-Influenza Antibodies
GSK terminated their collaboration with Vir to research, develop and commercialize the biotech’s monoclonal antibodies for the prevention, treatment, or prophylaxis of the influenza under a 2021 agreement.
February 23, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: European flags flap in the wind outside
Earlybird Health Hopes to Get the Worm with New $186M VC Fund
German-based Earlybird Health discussed its plans with BioSpace for its latest venture capital fund that will finance early-stage to late-stage European companies including biotech.
February 23, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Novavax/Getty Images, STR/NurPhoto
Policy
Novavax Reaches $400M Settlement with Gavi on COVID-19 Vaccine Purchase Agreement
The settlement, which includes an upfront $75 million payment to Gavi, ends arbitration related to a 2021 advance purchase agreement involving Novavax’s prototype vaccine NVX-CoV2373.
February 22, 2024
 · 
2 min read
 · 
Tyler Patchen
Load More